Improving Adherence to Inhaled Iloprost Treatment in Adults with Pulmonary Arterial Hypertension

What this Trial Is About

Pulmonary Arterial Hypertension PAH is a rare and progressive condition that affects blood flow in the lungs and can lead to heart failure. Despite advances in treatment, patients have a median survival of only 2.8 years. Current drugs focus on three pathways, including prostacyclin, which iloprost mimics in an inhaled form. However, iloprost requires frequent use and specific inhalation techniques, which can be challenging and cause side effects. This study evaluates if pharmacist guidance can improve how patients use iloprost, reduce side effects, and improve health outcomes. Participants will be randomly assigned to one of two groups one group will receive professional guidance on inhaler use and adherence, while the other will receive no intervention. The study focuses on the effects of pharmacist support in managing inhaled iloprost treatment over time. The intervention group aims to improve how patients manage their inhaled medication and adherence to the treatment plan. Participants will be followed for 20 weeks during which medication adherence will be measured using a specific questionnaire. Researchers will monitor patients for treatment adherence, side effects, and any difficulties with inhalation. The main outcome is to assess how well patients stick to their inhaled iloprost treatment when they receive pharmacist guidance compared to those who do not. This study is sponsored by the University of Sao Paulo General Hospital and aims to optimize treatment for PAH patients.

AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?